Indeed, in glioma cell lines, pharmacological AMPK activation with the compound A‐769662 increased mRNA and protein levels of PGC‐1α, which could be abrogated by addition of the p38 MAPK inhibitor SB220025 (Figure 4A and B). This evidence concerns the gene PPARGC1A and central nervous system cancer.